Last updated: 11/04/2018 05:38:26

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

Request patient level data
GSK study ID
B2C110165
See study documents
Clinicaltrials.gov ID
NCT00519376
See results summary
EudraCT ID
2007-001391-37
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients.
Trial description: This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by acting on cells in the lungs, causing some of the muscles around the lungs to relax and open up better (bronchodilation), making breathing easier. When a medicine is made into a form ready to be given to patients, the active ingredient is often prepared in the form of a salt, and inactive ingredients (excipients) are often added. Inactive ingredients might be used to help a medicine work better, to make it easier to produce the medicine, or to make it easier to get an accurate dose of medicine. In previous studies the study drug has been given as a dry powder in the form of either the ‘H’ salt (with the excipient lactose), or in the form of the ‘M’ salt (with the excipients lactose and cellobiose octaacetate). In this study the ‘M’ salt form of the study drug has been prepared with lactose and a new excipient called magnesium stearate (instead of cellobiose octaacetate). Participants in this study will receive both the ‘H’ salt (GW642444H) and the new ‘M’ salt (GW642444M) containing magnesium stearate. This study will be the first time the new ‘M’ salt form of the study drug will be given to COPD patients.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Number of participants with any adverse event (AE) or any serious adverse event (SAE) during the Treatment Period

Timeframe: From the first dose of the study medication until the Follow-up Visit (up to Study Day 60)

Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and white blood cell count at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in hemoglobin and mean corpuscle hemoglobin concentration (MCHC) at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in reticulocyte and red blood cell (RBC) count at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in hematocrit at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in mean corpuscle volume (MCV) at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in mean corpuscle hemoglobin (MCH) values at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in alanine amino transferase (ALT), alkaline phosphatase (ALP), aspartate amino transferase (AST), creatine kinase (CK) and gamma glutamyl transferase (GGT) values at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in albumin and total protein at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in cholesterol, chloride, potassium, sodium, triglycerides, and urea at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in total bilirubin and creatinine at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in c-reactive protein at 24 hours post-dose on Day 1 of each treatment period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over the post-dose 24 hour (h) period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in heart rate over the post-dose 24 hour (h) period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Change from Baseline in electrocardiographic (ECG) parameters over the post-dose 24 hour (h) period

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Secondary outcomes:

Mean FEV1 over 23 and 24 hours after dosing

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Weighted mean and maximum value (0 - 4 hours) QTc(B) and QTc(F)

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Weighted mean and maximum value (0 - 4 hours) supine heart rate

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Weighted mean and maximum value (0 - 4 hours) of supine systolic and diastolic blood pressure

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Weighted mean and maximum/minimum value (0 - 4 hours) for glucose and potassium

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

AUC(0- t) and up to 1 hour post-dose (AUC[0-1]) of GW642444 and its metabolites GI179710, GW630200, and GSK932009, after a single dose of GW642444

Timeframe: Baseline and Day 1 of each treatment period (up to Study Day 54)

Cmax of GW642444 and its metabolites GI179710, GW630200, and GSK932009, after a single dose of GW642444

Timeframe: Day 1 of each treatment period (up to Study Day 54)

Tmax of GW642444 and its metabolites GI179710, GW630200, and GSK932009, after a single dose of GW642444

Timeframe: Day 1 of each treatment period (up to Study Day 54)

Interventions:
Drug: GW642444M
Drug: GW642444H
Drug: placebo
Enrollment:
20
Observational study model:
Not applicable
Primary completion date:
2007-09-11
Time perspective:
Not applicable
Clinical publications:
Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256-64.
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
vilanterol
Collaborators
Not applicable
Study date(s)
August 2007 to November 2007
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
40+ years
Accepts healthy volunteers
No
  • Male or female (of non-childbearing potential) > or = 40 years
  • History of COPD
  • History of significant disease
  • Subjects with a primary asthma diagnosis
Inclusion and exclusion criteria
Inclusion criteria:
  • Male or female (of non-childbearing potential) > or = 40 years
  • History of COPD
  • Smoker or ex-smoker
  • Body weight > or = 50 kg with BMI 18-32 kg/m2
Exclusion criteria:
  • History of significant disease
  • Subjects with a primary asthma diagnosis
  • Alpha-1 antitrypsin deficiency as underlying cause of COPD
  • Recent respiratory tract infection
  • Poorly controlled COPD
  • Blood potassium level < 3.5mmol/L
  • Short-term or long tern oxygen therapy
  • Recent participation in another trial
  • History of drug or alcohol abuse
  • Known allergies
  • Recent blood donation
  • ECG abnormalities

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Wiesbaden, Hessen, Germany, 65187
Status
Will Be Recruiting
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 14050
Status
Will Be Recruiting
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 14057
Status
Will Be Recruiting
Contact us
Location
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55131
Status
Will Be Recruiting
Contact us

Study documents

Clinical study report
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2007-09-11
Actual study completion date
2007-09-11

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website